WVE-N531 - Wave Life Sciences
Viltepso (viltolarsen) - Nippon Shinyaku, National Center of Neurology and Psychiatry
Exondys 51 (eteplirsen) - Sarepta Therapeutics
Vyondys 53 (golodirsen) - Sarepta Therapeutics
delpacibart zotadirsen (KPE179) - Eli Lilly
zeleciment rostudirsen (DYNE-251) - Dyne Therap
brogidirsen (NS-089/NCNP-02) - Nippon Shinyaku, National Center of Neurology and Psychiatry
Duvyzat (givinostat) - Italfarmaco
Amondys 45 (casimersen) - Sarepta Therapeutics
https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2026/poster-session-1-4/expert-consensus-on-treatment-guidance-for-fda-approved-and-second-generation-exon-skipping-therapies-in-duchene-muscular-dystrophy-dmd--a-rand-ucla-modified-delphi-panel
 
Edward Smith, MD 1; Lindsay Alfano, PT, DPT, PCS 2; John Brandsema, MD 3; Tina Duong, MPT, PhD 4; Katherine Mathews, MD 5; Leigh Maria Ramos-Platt, MD 6; Aravindhan Veerapandiyan, MD 7; Brenda Wong, MD 8; Craig Zaidman, MD 9; Justin Weiss, MPH 10; Irina Yermilov, MPH, MS, MD 11
 
Mar 6, 2026
 
Prev Next